Accuray Inc ARAY
We take great care to ensure that the data presented and summarized in this overview for ACCURAY INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARAY
View all-
Tcw Group Inc11.9MShares$12.7 Million0.18% of portfolio
-
Black Rock Inc. New York, NY8.23MShares$8.81 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.48MShares$5.86 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY5.28MShares$5.65 Million0.01% of portfolio
-
Heartland Advisors Inc Milwaukee, WI5MShares$5.35 Million0.45% of portfolio
-
Armistice Capital, LLC New York, NY3.32MShares$3.56 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA2.49MShares$2.66 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.48MShares$2.66 Million0.01% of portfolio
-
Acuitas Investments, LLC2.39MShares$2.56 Million3.01% of portfolio
-
State Street Corp Boston, MA1.99MShares$2.13 Million0.0% of portfolio
Latest Institutional Activity in ARAY
Top Purchases
Top Sells
About ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Insider Transactions at ARAY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Sandeep Chalke SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
64,477
-12.3%
|
$64,477
$1.02 P/Share
|
|
Dec 01
2025
|
Ali Pervaiz SVP Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
57,341
-13.98%
|
$57,341
$1.02 P/Share
|
|
Nov 29
2025
|
Sandeep Chalke SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,314
+8.76%
|
-
|
|
Nov 29
2025
|
Ali Pervaiz SVP Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,025
+9.69%
|
-
|
|
Nov 28
2025
|
Steven F Mayer |
BUY
Grant, award, or other acquisition
|
Direct |
895,391
+40.87%
|
-
|
|
Nov 28
2025
|
Chan Galbato |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Nov 21
2025
|
James M. Hindman |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+16.11%
|
-
|
|
Nov 21
2025
|
Beverly A Huss |
SELL
Payment of exercise price or tax liability
|
Direct |
22,642
-9.28%
|
$22,642
$1.05 P/Share
|
|
Nov 21
2025
|
Beverly A Huss |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+18.83%
|
-
|
|
Nov 21
2025
|
Anne Bryce Le Grand |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+17.91%
|
-
|
|
Nov 21
2025
|
Steven F Mayer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,620
+10.23%
|
-
|
|
Nov 21
2025
|
Mika Nishimura |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+21.02%
|
-
|
|
Nov 21
2025
|
Byron C Scott |
SELL
Payment of exercise price or tax liability
|
Direct |
22,642
-12.87%
|
$22,642
$1.05 P/Share
|
|
Nov 21
2025
|
Byron C Scott |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+24.34%
|
-
|
|
Nov 21
2025
|
Joseph E Whitters |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+7.82%
|
-
|
|
Nov 19
2025
|
Stephen R. La Neve CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.97 P/Share
|
|
Nov 13
2025
|
Robert Kill |
BUY
Exercise of conversion of derivative security
|
Direct |
56,603
+25.8%
|
-
|
|
Oct 31
2025
|
Steven F Mayer |
BUY
Grant, award, or other acquisition
|
Direct |
354,609
+50.0%
|
-
|
|
Oct 31
2025
|
Michael John Murphy VP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
12,001
-32.0%
|
$12,001
$1.41 P/Share
|
|
Oct 31
2025
|
Michael John Murphy VP, Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+50.0%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 574K shares |
|---|---|
| Grant, award, or other acquisition | 1.3M shares |
| Open market or private purchase | 70K shares |
| Payment of exercise price or tax liability | 237K shares |
|---|